<DOC>
	<DOCNO>NCT02722694</DOCNO>
	<brief_summary>The primary objective study demonstrate superior efficacy abatacept 125mg administrated SC weekly comparing placebo 24 week treatment Chinese subject active rheumatoid arthritis , receive methotrexate experience inadequate response methotrexate . This estimated proportion subject meeting American College Rheumatology ( ACR ) criteria 20 % improvement ( ACR20 ) .</brief_summary>
	<brief_title>A Phase 3 Study Abatacept Chinese Patients With Active Rheumatoid Arthritis Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Subjects willing participate study sign inform consent ; Subjects must meet criterion America Rheumatism Association ( 1987 ) diagnosis rheumatoid arthritis ACR ( 1991 ) functional class I , II III ; Subjects must Rheumatoid Arthritis least 6 month ; Subjects inadequately response MTX , must take methotrexate least 3 month minimal dose 10 mg weekly , stable dose least 28 day prior randomization ( Day 1 ) . Methotrexate weekly dose low 7.5 mg permit subject tolerate high dose , intolerance high dose 7.5mg weekly well document ; Subjects must follow disease activity randomization : 1 . 6 swollen joint ( 66 joint count ) ; 2 . 8 tender joint ( 68 joint count ) ; 3 . C reactive protein ( hsCRP ) &gt; 3 mg/L ( base result screen visit ) ESR ≥ 28mm/hr ; All DMARDs ( except methotrexate ) discontinue least 28 day prior study randomization ( Day 1 ) , Leflunomide must discontinue ≥8 week ( subject washedout cholestyramine accord label recommendation ) ; Oral corticosteroid treatment must reduce prednisone ≤ 10 mg daily equivalent 28 days，and stabilize least 25 28 day prior randomization ( Day 1 ) . Corticosteroid administer intraarticular ( IA ) intramuscular ( IM ) allow 28 day prior randomization ( Day 1 ) ; Stable NSAIDs permit ; Male female subject ≥18 year old ; Women childbearing potential ( WOCBP ) must negative pregnancy test within 24 hour prior start study medication ; WOCBP male patient childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period 10 week last dose study medication ; Women pregnant breastfeeding ; Women positive pregnancy test enrollment prior study drug administration ; Subjects meet diagnosis criterion rheumatoid disease ( e.g. , systemic lupus erythematosus ) ; Subjects active vasculitis major organ system ( except subcutaneous rheumatoid nodule ) ; Current symptom severe , progressive uncontrolled disease renal , hepatic , hematological , gastrointestinal , pulmonary , cardiac , neurological , cerebral . Concomitant medical condition , opinion investigator , might place subject unacceptable risk participation study ; Subjects history cancer within last five year ( nonmelanoma skin cell cancer cure local resection ) . Existing nonmelanoma skin cell cancer must remove prior dose . Subjects carcinoma situ , treat definitive surgical intervention , allow ; Subjects history drug alcohol abuse ; Subjects serious bacterial infection within last 3 month ( pneumonia pyelonephritis , unless treat resolved antibiotic ) ; Subjects serious , chronic recurrent bacterial infection ( recurrent pneumonia chronic bronchiectasis ) ; Subjects risk tuberculosis ( TB ) , Specially , : 1 . Having evidence clinical , image lab test current active latent pulmonary tuberculosis ; 2 . Having active pulmonary tuberculosis past 3 year , even treat ; 3 . Having history active pulmonary tuberculosis 3 year ago , unless appropriate duration type antituberculosis drug well document ; Subjects herpes zoster resolve less 2 month enrollment ; Subjects evidence ( assessed Investigator ) active latent bacterial viral infection time potential enrollment , include subject evidence Human Immunodeficiency Virus ( HIV ) infection ; Subjects impair , incapacitate , incapable complete study related assessment ; HepatitisB surface antigenpositive subject . Hepatitis C antibodypositive subject HIV antibodypositive subject Subjects follow laboratory value : 1 . Hgb &lt; 85 g/L 2. white blood cell count &lt; 3,000/mm3 ( 3×10^9/L ) 3 . Platelets &lt; 100,000/mm3 ( 100×10^9/L ) ; 4 . Creatinine clearance &lt; 40 mL/min ; 5 . Serum glutamic pyruvic transaminase ( GPT ALT ) glutamic oxaloacetic transaminase ( GOT AST ) &gt; 2 time upper limit normal ; 6 . Any laboratory test result , opinion Investigator , might place subject unacceptable risk participation study ; Subjects receive treatment rituximab time ; Subjects prior exposure abatacept CTLA4Ig ; Subjects receive treatment investigational drug within 28 day ( less 5 terminal halflives elimination ) ( whichever longer ) ; Subjects currently ( sign inform consent ) treat antitumor necrosis factor ( TNF ) therapy , adalimumab infliximab ( within 8 week last dose ) , etanercept ( within 4 week last dose ) ; Subjects discontinue approve biologic RA therapy due lack efficacy past ; Subjects expose multiple ( &gt; 3 ) approve biologic RA therapy past ; Subjects currently treat anakinra unless minimum 4week washout period complete Day 1 ; Subjects receive prior treatment investigational biologic currently approve ; Subjects expose approve biologic within 4 week 5 halflives , whichever longer ; Subjects ( sign inform consent ) receive investigational biologic RA therapy approve biologic RA therapy ; Subjects receive active vaccine within 3 month first dose study medication plan receive active vaccine study ; Prisoners subject involuntarily incarcerate ; Subjects compulsorily detain treatment either psychiatric physical ( e.g. , infectious disease ) illness ; Subjects illiterate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>